PL2948157T3 - Zastosowanie genetycznie zmodyfikowanego zakaźnego wirusa odry o wzmocnionych właściwościach proapoptotycznych (wirusa MV-deltaC) w terapii nowotworów - Google Patents
Zastosowanie genetycznie zmodyfikowanego zakaźnego wirusa odry o wzmocnionych właściwościach proapoptotycznych (wirusa MV-deltaC) w terapii nowotworówInfo
- Publication number
- PL2948157T3 PL2948157T3 PL14701698T PL14701698T PL2948157T3 PL 2948157 T3 PL2948157 T3 PL 2948157T3 PL 14701698 T PL14701698 T PL 14701698T PL 14701698 T PL14701698 T PL 14701698T PL 2948157 T3 PL2948157 T3 PL 2948157T3
- Authority
- PL
- Poland
- Prior art keywords
- virus
- deltac
- genetically modified
- cancer therapy
- apoptotic properties
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18461—Methods of inactivation or attenuation
- C12N2760/18462—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305086.4A EP2759301A1 (en) | 2013-01-24 | 2013-01-24 | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus) |
| PCT/EP2014/051063 WO2014114605A1 (en) | 2013-01-24 | 2014-01-20 | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in cancer therapy |
| EP14701698.4A EP2948157B1 (en) | 2013-01-24 | 2014-01-20 | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2948157T3 true PL2948157T3 (pl) | 2019-03-29 |
Family
ID=47683672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14701698T PL2948157T3 (pl) | 2013-01-24 | 2014-01-20 | Zastosowanie genetycznie zmodyfikowanego zakaźnego wirusa odry o wzmocnionych właściwościach proapoptotycznych (wirusa MV-deltaC) w terapii nowotworów |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9889193B2 (pl) |
| EP (2) | EP2759301A1 (pl) |
| JP (1) | JP6382223B2 (pl) |
| CN (1) | CN107223055A (pl) |
| BR (1) | BR112015017692B1 (pl) |
| CA (1) | CA2898370C (pl) |
| DK (1) | DK2948157T3 (pl) |
| ES (1) | ES2700749T3 (pl) |
| PL (1) | PL2948157T3 (pl) |
| RU (1) | RU2700083C2 (pl) |
| WO (1) | WO2014114605A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2759301A1 (en) * | 2013-01-24 | 2014-07-30 | Institut Pasteur | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus) |
| CN107085095A (zh) * | 2017-03-02 | 2017-08-22 | 江苏华冠生物技术股份有限公司 | 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法 |
| WO2019106205A1 (en) * | 2017-12-01 | 2019-06-06 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7118740B1 (en) | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
| EP2110382A1 (en) | 2002-06-20 | 2009-10-21 | Institut Pasteur | Infectious cDNA of an improved vaccine strain of measles virus, use for immunogenic compositions |
| CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| CA2508266A1 (fr) | 2005-06-20 | 2006-12-20 | Institut Pasteur | Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae |
| EP1939214B1 (en) | 2006-12-22 | 2013-07-10 | Institut Pasteur | Cells and methodology to generate non-segmented negative-strand RNA viruses |
| EP2058003A1 (en) * | 2007-10-10 | 2009-05-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Medicaments and methods for treating mesothelioma |
| EP2420242A1 (en) * | 2010-08-20 | 2012-02-22 | Lauer, Ulrich M. | Oncolytic measles virus |
| US9399062B2 (en) * | 2011-01-18 | 2016-07-26 | Christopher D. Richardson | PVRL4 (Nectin4) is a receptor for measles virus |
| EP2759301A1 (en) * | 2013-01-24 | 2014-07-30 | Institut Pasteur | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus) |
-
2013
- 2013-01-24 EP EP13305086.4A patent/EP2759301A1/en not_active Withdrawn
-
2014
- 2014-01-20 PL PL14701698T patent/PL2948157T3/pl unknown
- 2014-01-20 BR BR112015017692-5A patent/BR112015017692B1/pt not_active IP Right Cessation
- 2014-01-20 EP EP14701698.4A patent/EP2948157B1/en active Active
- 2014-01-20 CA CA2898370A patent/CA2898370C/en active Active
- 2014-01-20 RU RU2015128913A patent/RU2700083C2/ru active
- 2014-01-20 CN CN201480017539.6A patent/CN107223055A/zh active Pending
- 2014-01-20 ES ES14701698T patent/ES2700749T3/es active Active
- 2014-01-20 DK DK14701698.4T patent/DK2948157T3/en active
- 2014-01-20 WO PCT/EP2014/051063 patent/WO2014114605A1/en not_active Ceased
- 2014-01-20 JP JP2015554120A patent/JP6382223B2/ja active Active
- 2014-01-20 US US14/762,559 patent/US9889193B2/en active Active
-
2018
- 2018-01-25 US US15/880,133 patent/US10314905B2/en active Active
-
2019
- 2019-06-03 US US16/429,571 patent/US10980873B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9889193B2 (en) | 2018-02-13 |
| BR112015017692B1 (pt) | 2021-11-03 |
| CN107223055A (zh) | 2017-09-29 |
| CA2898370A1 (en) | 2014-07-31 |
| EP2759301A1 (en) | 2014-07-30 |
| BR112015017692A2 (pt) | 2019-11-19 |
| US10314905B2 (en) | 2019-06-11 |
| CA2898370C (en) | 2020-01-14 |
| RU2015128913A (ru) | 2017-03-02 |
| EP2948157B1 (en) | 2018-10-10 |
| DK2948157T3 (en) | 2019-01-07 |
| JP2016506722A (ja) | 2016-03-07 |
| ES2700749T3 (es) | 2019-02-19 |
| US10980873B2 (en) | 2021-04-20 |
| US20200016260A1 (en) | 2020-01-16 |
| WO2014114605A1 (en) | 2014-07-31 |
| US20150359873A1 (en) | 2015-12-17 |
| US20180221469A1 (en) | 2018-08-09 |
| RU2700083C2 (ru) | 2019-09-12 |
| EP2948157A1 (en) | 2015-12-02 |
| JP6382223B2 (ja) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264385B (en) | Newcastle disease viruses and their use | |
| IL261204A (en) | Influenza virus vaccines and their use | |
| IL244254A0 (en) | Engineered anti-dll3 conjugates and methods of use | |
| IL244665A0 (en) | Conjugates of chlorotoxin and methods of using them | |
| SG11201602838UA (en) | Safe socket and use thereof | |
| IL245312B (en) | Recombinant oncolytic herpes simplex virus | |
| ZA201509229B (en) | Influenza virus vaccines and uses thereof | |
| DK2903600T3 (da) | Virusholdig formulering og anvendelse deraf | |
| HUE043463T2 (hu) | Vírusszerû részecske konjugátumok tumorok kezelésére | |
| PL3088353T3 (pl) | Cząstki bilirubiny i ich wytwarzanie do zastosowania w terapii | |
| PL2935313T3 (pl) | Szczepionki przeciwko wirusowi zapalenia wątroby typu b | |
| ZA201501639B (en) | Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same | |
| ZA201701643B (en) | Pyrrolopyrimidines for use in influenza virus infection | |
| EP3046565A4 (en) | Papaya mosaic virus and virus-like particles in cancer therapy | |
| EP2974740A4 (en) | HEPATITIS B VACCINE | |
| EP2806890A4 (en) | COMPOSITIONAL ANTIGEN SEQUENCES AND VACCINES | |
| PL2969005T3 (pl) | Atenuowane wirusy grypy i szczepionki | |
| SG11201509265SA (en) | Avoiding narcolepsy risk in influenza vaccines | |
| IL244750A0 (en) | Autologous tumor vaccines and methods | |
| SG11201604301VA (en) | Piperidine and piperazine derivatives and their use in treating viral infections and cancer | |
| CL2015003706A1 (es) | Composiciones vacunales bivalentes y su uso para la terapia de tumores | |
| EP3068411A4 (en) | Oncolytic viruses and increased cancer treatment regimens | |
| GB201301119D0 (en) | Viral vaccines | |
| SG11201507455WA (en) | Hepatitis b virus vaccines | |
| GB201323103D0 (en) | HIV vaccine and cure |